ALK-208

N/A

Report date: 2026/05/09 20:00:18

First In Class

Base Information

Drug NameALK-208

Drug Alias NameALK-208ALK208ALK 208

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-Vascular endothelial growth factorAnti-Programmed death-ligand 1Anti-CD276 +[4]

TargetsVascular endothelial growth factorProgrammed death-ligand 1CD276 antigen +[4]

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesShanghai Allink Biotherapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Allink Biotherapeutics Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A